当前位置: 首页 > 期刊 > 《动脉硬化血栓血管生物学》 > 2005年第2期 > 正文
编号:11275568
Are Circulating CD133+ Cells Biomarkers of Vascular Disease?
http://www.100md.com 《动脉硬化血栓血管生物学》
     From the Department of Exercise Science, University of Iowa, Iowa City.

    Correspondence to Gina Schatteman, 406 Field House, Department of Exercise Science, University of Iowa, Iowa City, IA 52242-1111. E-mail gina-schatteman@uiowa.edu

    Single cell bone marrow transplantation leaves no doubt as to the ability of bone marrow cells to differentiate and integrate into the endothelium, though the physiological significance of this remains controversial. Reported rates of bone marrow cell integration into the endothelium after injury vary widely, ranging from almost no cells to large percentages. Bone marrow cell maintenance of the quiescent (ie, nongrowing) vasculature has been less well studied, but at least one mouse study suggests it could be significant.1 Whether or not large numbers of circulating cells integrate into the vessel wall, a consensus seems to be emerging that circulating bone marrow–derived cells can promote vascular growth. Exactly how this is accomplished is not clear, though it is presumably due to release of proangiogenic factors.

    See page 296

    Mobilization of various circulating endothelial cell progenitor (CEP)–containing populations correlates with increased vascularization in tissues undergoing neovascularization, and vascular trauma including burns, coronary artery bypass graft, and myocardial infarct all mobilize CEPs.2–6 In light of these findings, the loss or dysfunction of CEPs could impact on vascular health. Hence, over the past several years a number of studies have begun to examine whether there is a relationship between CEP function and vascular disease. Of course, to do this, one must define a CEP. Therein lies the rub. No consensus has been reached as to what constitutes a CEP, and each laboratory seems to use a different definition. Generally speaking, CEP-containing populations that have been studied fall into two broad categories: cells related to hematopoietic stem cells and cells (probably) of the myeloid lineage. Hematopoietic stem cell–related populations are though to yield "late outgrowth colonies" when plated in conditions that promote endothelial cell differentiation. Late outgrowth colonies derive from the nonadherent mononuclear cells and arise only after long-term culture. In contrast, myeloid lineage cells probably are the predominant source of "EPCs," endothelial-like cells that derive from 4 day cultures of adherent mononuclear cells.

    Among hematopoietic stem cell–related populations, CD133+, CD34+, and VEGFR+ cells have received a great deal of attention. In early experiments, expression of CD34 or mouse VEGFR2 was used to identify CEPs,7 but both of these antigens are expressed on endothelial cells. To exclude differentiated circulating endothelial cells from a study population, CD133+ has been adopted as a marker for primitive CEP, because CD133 is not known to be expressed by endothelial cells. In some circumstances this is a critical distinction, because some disease and injury states can increase the number of circulating endothelial cells. Thus, although the rare CD133+ cells or subsets thereof by no means represent all CEPs, they may be useful for examining how disease affects the most primitive CEP populations. Further, because presumably all other CEPs ultimately derive from CD133+ cells, this may be an important population to follow.

    In an article in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Powell et al report that coronary artery disease (CAD) correlates with a 5-fold reduction in the fraction of three different subsets of circulating CD133+ cells: CD133+CD34+, CD133+CXCR4+, and CD133+VEGFR2+ cells.8 Because of a possible sustained inflammatory state in CAD patients, the reduction in the absolute number of circulating CD133+ cells might be somewhat less than the percentages suggest, but mobilization of total mononuclear cells is unlikely to account for the bulk of it. Thus, it appears that CAD reduces both the fraction and total number of primitive CEPs regardless of which subset one chooses to assay. More importantly, loss of each of these populations may be indicative of the loss of different functional activities of CEPs. CD133+CD34+ are probably the most primitive of the circulating progenitors, so the loss of other CEP populations may be a direct consequence of the reduction in CD133+CD34+ cells. Because SDF-1 is thought to be essential for CEP homing, loss of CD133+CXCR4+ cells could significantly impact on the recruitment of CEPs to sites of injury. Finally, CD133+VEGFR2+ cells may represent CEPs that are committed to differentiate down the endothelial cell pathway, and their loss may compromise the ability of CEPs to differentiate into endothelial cells.

    The authors also show that all three CD133+ mononuclear cell populations are effectively mobilized by granulocyte-colony stimulating factor (G-CSF). Yet, although the fold-reduction in CD133+ cells is similar for the three CD133+ subsets, the fold mobilization differs among the populations and relative to mobilization of the same populations in healthy controls. Thus, although therapeutic mobilization of CEPs may be possible in CAD and other patient groups, the choice of mobilizing agent may be critical, because each is likely to mobilize a different subset of CD133+ cells. Further, there is some evidence that G-CSF mobilization may be harmful in certain clinical settings, so it may not represent an ideal mobilizing agent.9 Also, one might speculate that the affected subset(s) of CD133+ cells might be disease-specific, as would then be the appropriate mobilizing agent.

    The Powell study also examines whether the loss of primitive CEPs is functionally significant, by measuring the ability of nonadherent mononuclear cells to form late outgrowth colonies. Cells derived from CAD patients formed almost no colonies, but the ability to form colonies was restored to levels of healthy controls after treatment of the patients with G-CSF. Unlike an earlier study that assayed EPC formation by cells from CAD patients,10 there was no correlation between the number of risk factors for CAD and the ability to form colonies among CAD patients. However, there did appear to be an association between the number of risk factors and colony formation among healthy patients.

    Thus, CD133+ cells may prove to be a useful biomarker of vascular disease. Still, though there is an association between the loss of circulating CD133+ cells and CAD, that this translates to a loss of CEPs has not been proven. This cannot happen until we know the precise phenotypes of CEPs. Further, decreases in EPCs or late outgrowth colonies could be due to changes in CEPs that render them less able to survive, proliferate, or differentiate in culture. In support of this, simvastatin both induced proliferation and increased survival under stress of EPCs in culture.11 Careful analysis of plating efficiencies, apoptosis, proliferation, and related parameters will be needed before more definitive conclusions can be reached. Nevertheless, it is clear that vascular disease does alter CEP function, and all evidence suggests that this is not for the better.

    References

    Crosby JR, Kaminski WE, Schatteman GC, Martin JC, Raines EW, Seifert RA, Bowen-Pope DF. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000; 87: 728–730.

    Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res. 2001; 88: 167–174.

    Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001; 103: 2776–2779.

    Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5: 434–438.

    Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc Biol. 2004; 24: 684–690.

    Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004; 109: 220–226.

    Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–967.

    Powell TM, Paul JD, Hill JM, Thompson M, Benjamin M, Rodrigo M, McCoy JP, Read EJ, Khuu HM, Leitman SF, Finkel T, Cannon RO 3rd. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2005: 25: 296–301.

    Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo Lee D, Sohn DW, Han KS, Oh BH, Lee MM, Park YB. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 2004; 363: 751–756.

    Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001; 89: E1–E7.

    Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. 3hydroxy3methylglutaryl (HMG)-coenzymeA (CoA) reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells. J Clin Invest. 2001; 108: 399–405.(Gina Schatteman)